N
ONC icon

Natixis’s BeOne Medicines Ltd ONC Stock Holding History

Natixis’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-58,173
Closed -$16.7M – 1113
2020
Q3 		$16.7M Buy
+58,173
New +$13.7M 0.12% 153
2020
Q2 		– Sell
-34,437
Closed -$4.24M – 875
2020
Q1 		$4.24M Buy
+34,437
New +$5.39M 0.03% 292
2019
Q2 		– Sell
-25,077
Closed -$3.17M – 920
2019
Q1 		$3.17M Sell
25,077
-63
-0.3% -$8.5K 0.02% 437
2018
Q4 		$3.53M Buy
+25,140
New +$3.33M 0.03% 368

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Natixis's ONC Position: Q4 2020 in Review

Natixis sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 58,173 shares — an estimated $16.7M sold.

Natixis first reported a position in ONC in Q4 2018 and held it in 4 quarters. The position peaked at $16.7M in Q3 2020. 248 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

  • Natixis reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
  • Natixis sold 58,173 BeOne Medicines Ltd shares in Q4 2020, an estimated $16.7M.
  • Natixis first reported a position in BeOne Medicines Ltd in Q4 2018 and held it in 4 quarters.
  • Natixis's BeOne Medicines Ltd position peaked at $16.7M in Q3 2020.
  • 248 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Natixis's 13F filing for Q4 2020, filed 12 Feb 2021.